Clinical trial
Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%
NCT00101673 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2004
- Completion date
- June 30, 2005
- Enrollment
- 251 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.